BioSpace News Archive

Drug Development

Neurana Pharmaceuticals Announces First Patient Enrolled in the “STAR Study” a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back

Neurana Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has enrolled its first patient in the “STAR Study,” a Phase 2 dose ranging study of tolperisone in acute muscle spasms of the back.

February 4, 2019

·

2 min read

BioCapital

Paul Ryan To Speak In San Diego Feb. 21 At 2019 NIC Spring Conference

Former Speaker of the U.S. House of Representatives Paul Ryan will offer insight on what to expect from the new Congress and the impact on America’s seniors

February 4, 2019

·

2 min read

Pharm Country

Dr. Reddy’s Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy’s Laboratories Ltd. announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL single-dose infusion bags to the hospital level in U.S.A.

February 4, 2019

·

7 min read

Policy

CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the CHMP has adopted a positive opinion for Praluent® Injection

February 4, 2019

·

13 min read

Business

Macherey-Nagel GmbH & Co. KG and Andrew Alliance Sign Co-Marketing Agreement

Macherey-Nagel GmbH & Co. KG and Andrew Alliance announced they have signed an agreement stating that they are working together to develop an automated solution for the preparation of transfection grade plasmid DNA.

February 4, 2019

·

1 min read

Business

argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology

argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn

February 4, 2019

·

8 min read

Drug Development

GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)

Mean best-corrected visual acuity (BCVA) among GS010-treated eyes and sham-treated eyes evolved with similar trajectories, worsening to a low point, or nadir, before beginning to improve by Week 48 – coherent with REVERSE trial

February 4, 2019

·

13 min read

Elekta: New Study to Learn From Every Cancer Patient Treated With Magnetic Resonance Radiation Therapy

The MOMENTUM study is a transformative approach to evaluating innovative medical technology

February 4, 2019

·

5 min read

Biotech Beach

Johnson & Johnson Vision Announces Availability in Europe of TECNIS Eyhance IOL, a Next-Generation Monofocal Intraocular Lens for Patients with Cataracts

TECNIS Eyhance IOL is the latest innovation in the industry leading TECNIS® Family of Intraocular Lenses

February 4, 2019

·

10 min read

Business

QIAGEN Informatics Solutions Chosen to Support Genomics England’s Bold Five Million Genomes in Five Years Project

QCI is a powerful, high quality decision support solution for rapid interpretation of hereditary diseases

February 4, 2019

·

1 min read